Pathology/Lab Coding Alert

Boost Glycosylated Hemoglobin Payments With New Code

Watch out:  Physician must document reason for frequent A1C

Diabetes management may require hemoglobin A1C testing--but you won't get paid if you miss the frequency mark.

You may know the test by various names: glycated or glycosylated Hgb, or A1C. You can use the 2006  A1C code changes to refresh your skills for reporting this service.

The American Diabetes Association (ADA) recommends that in addition to patients monitoring their blood glucose levels at home, they should also receive hemoglobin A1C testing. The latter test reveals the patient's average blood glucose level, or glycemic control, over the preceding four to eight weeks. The lower the patient's value, the better he is maintaining normal blood sugar.

"Hemoglobin A1C is the standard for monitoring type 1 and type 2 diabetes," says Nathaniel Clark, MD, MS, RD, of the ADA. Learn CPT 2006 Code Changes To better reflect current nomenclature, CPT 2006 changed the word "glycated" to "glycosylated" for 83036 (Hemoglobin; glycosylated [A1C]). The physician might also order the test as "hemoglobin A1C."

Don't miss: The U.S. Food and Drug Administration recently approved a home-use device for measuring glycosylated hemoglobin. If you use the devise for point-of-care testing, you should report the service with new code CPT 83037 (Hemoglobin; glycosylated [A1C] by device cleared by FDA for home use).

Physicians find having A1C results available valuable during the patient visit. That's why they might have the patient test at home or may offer point-of-care testing using the FDA-approved device. You should report these tests as 83037.

Otherwise, the lab often receives a request for the test a few days before the physician visit and reports 83036 for the standard A1C lab test, usually determined by ion-exchange affinity chromatography, immunoassay, or agar gel electrophoresis. Then the physician may counsel the patient about the test results at the visit. Watch Frequency Limits Medicare's National Coverage Determination (NCD) for glycated hemoglobin provides frequency guidelines for patients who are capable of maintaining long-term, stable glycemic control: "Measurement may be medically necessary every three months to determine whether a patient's metabolic control has been, on average, within the target range."

Diabetes experts agree. Physicians should order the A1C test every three to six months with a target of under 7 percent, says Beverly Dyck Thomassian, RN, MPH, BC-ADM, CDE, a diabetes educator in Chico, Calif.

But what if the patient doesn't have long-term, stable glycemic control? According to the NCD, "More frequent assessments, every one to two months, may be appropriate in the patient whose diabetes regimen has been altered to improve control or in whom evidence is present that intercurrent events may have altered a previously satisfactory level of control." Events that might alter glycemic control include major surgery or glucocorticoid [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Pathology/Lab Coding Alert

View All